IGF2 and neoplasm: Considering that the upregulation of IR and IGF2 after IGF2BP3 depletion did not appear to be a general phenomenon, reflective of heterogeneity in tumor response, we strongly advocate for the need to evaluate the IGF1R/IR ratio together with the expression of IGF2BP3 to predict therapeutic response to agents targeting IGF1R and/or IR before and during any treatment.